Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Amgen Offers $1.9 Billion to Acquire Five Prime Therapeutics
March 5, 2021 (Investorideas.com Newswire) Five Prime Therapeutics shares traded 78% higher after the company reported it entered into a definitive agreement to be acquired by biotech giant Amgen for $38 per share in cash.

FDA Grants Expanded Use in General Surgery for Asensus Surgical's Robotic Laparoscopic Platform
March 4, 2021 (Investorideas.com Newswire) Asensus Surgical shares traded 16.5% higher after the company reported it received clearance from the U.S. Food & Drug Administration for its Senhance Surgical System for use in general surgical procedures.

U.S. Biopharma Making a 'Bold Move into a Large Market Opportunity'
March 4, 2021 (Investorideas.com Newswire) This latest undertaking of Dicerna Pharmaceuticals and the near-term catalysts of some of its other programs are described in an H.C. Wainwright & Co. report.

Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck
ebruary 26, 2021 (Investorideas.com Newswire) Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share.

Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook
February 25, 2021 (Investorideas.com Newswire) Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures.

Analyst: All Systems Are Go for Testing, Testing and More Testing
February 25, 2021 (Investorideas.com Newswire) This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing.

Telehealth Tech Company Continues Rapid Growth in COVID-Changed Landscape
February 25, 2021 (Investorideas.com Newswire) Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians.

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
February 18, 2021 (Investorideas.com Newswire) New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report.

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer
February 18, 2021 (Investorideas.com Newswire) Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals.

Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition
February 18, 2021 (Investorideas.com Newswire) Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. This new EMA designation provides NervGen with...

Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has appointed Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system, to its scientific advisory board ("Scientific Advisory Board"). Dr. Gabriele specializes in molecular pharmacology, transdermal delivery and formulation chemistry with pharmaceutical, natural molecules. In his role on Mindset's Scientific Advisory Board, Dr....

Universal PropTech Inc. Announces Option Grant
Toronto, Ontario--(Newsfile Corp. - March 5, 2021) - Universal PropTech Inc. (TSXV: UPI) (FSE:8LH) ("UPI" or the "Company") announces today that it has granted an aggregate of 500,000 options to a consultant pursuant to the Company's stock option plan. The stock options vest immediately at an exercise price of $0.45 for a period of three years from the date of grant. The grant of options is subject to the approval of the TSX Venture...

Tryp Therapeutics Announces Application to List on OTCQB
La Jolla, California--(Newsfile Corp. - March 4, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market ("OTCQB").The Financial Industry Regulatory Authority or FINRA has accepted the Company's Form 211, which qualifies the Company's shares to trade in the United States on...

Initial Insurance Billing Codes Issued for Dedicated Breast CT in The USA
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic"), a company developing high-resolution 3D dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers, is pleased that the American Medical Association (AMA) has released six Category III CPT billing codes for Breast CT technology. The AMA issuance of these initial insurance billing codes spotlights dedicated breast CT as a promising emerging...

Subscribe to Biotech News